GDRX250117C10000
- 0.03
- 0.000.00%
GoodRx Newsroom
Mizuho Securities Maintains GoodRx(GDRX.US) With Hold Rating
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects
GoodRx Holdings Analyst Ratings
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $6
Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Cuts Target Price to $6
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $9
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $4.5
Sell Rating Maintained for GoodRx Holdings Amid Volatility and Strategic Challenges
Positive Outlook for GoodRx Holdings Under New Leadership: Buy Rating and 52.5% Potential Return
Mizuho Initiates GoodRx Holdings at Neutral With $5 Price Target
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)
Leerink Partners Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Cuts Target Price to $7
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $8.5
GoodRx Holdings (GDRX) Gets a Buy From RBC Capital
A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $5 to $7
GoodRx Holdings Is Maintained at Overweight by Barclays